Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $510 | $3,280 | $2,835 | $10,954 |
| - Cash | $562 | $944 | $1,316 | $1,550 |
| + Debt | $468 | $239 | $443 | $23 |
| Enterprise Value | $416 | $2,576 | $1,961 | $9,427 |
| Revenue | $227 | $251 | $478 | $314 |
| % Growth | -9.7% | -47.4% | 52.2% | – |
| Gross Profit | $188 | $197 | $273 | $184 |
| % Margin | 83% | 78.5% | 57.3% | 58.7% |
| EBITDA | -$484 | -$821 | -$2,060 | -$1,807 |
| % Margin | -213.3% | -326.6% | -431.2% | -575.7% |
| Net Income | -$547 | -$893 | -$2,105 | -$1,830 |
| % Margin | -240.9% | -355.1% | -440.6% | -583.1% |
| EPS Diluted | -10.54 | -18.4 | -50.2 | -55.53 |
| % Growth | 42.7% | 63.3% | 9.6% | – |
| Operating Cash Flow | -$320 | -$296 | -$252 | -$254 |
| Capital Expenditures | -$63 | -$41 | -$52 | -$57 |
| Free Cash Flow | -$382 | -$336 | -$304 | -$310 |